27.10.2011 29.Tischrei. 5772
Biogen's BG-12, which is administered orally, was shown to be more effective than Teva's drug Copaxone, delivered by injection. It was also more effective than Laquinimod, an oral version of Copaxone that Teva is developing.
The first round in the battle between Teva Pharmaceutical Industries and Biogen Idec over multiple sclerosis therapy was fought a week ago. That match, at a medical conference in Amsterdam, ended in a tie with a slight advantage to Biogen. Yesterday Biogen published the initial results of a late-stage clinical trial of BG-12 and won Round 2 hands-down….